Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol

Anthony Gunnell, Matthew Knuiman, Elizabeth Geelhoed, Michael Hobbs, Judith Katzenellenbogen, Joe Hung, J.M. Rankin, Lee Nedkoff, Tom Briffa, M. Ortiz, M. Gillies, A. Cordingley, M. Messer, Christian Gardner, Derrick Lopez, Emily Atkins, Qun Mai, Frank Sanfilippo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction
Secondary prevention drugs for cardiac disease have been demonstrated by clinical trials to be effective in reducing future cardiovascular and mortality events (WAMACH is the Western Australian Medication Adherence and Costs in Heart disease study). Hence, most countries have adopted health policies and guidelines for the use of these drugs, and included them in government subsidised drug lists to encourage their use. However, suboptimal prescribing and non-adherence to these drugs remains a universal problem. Our study will investigate trends in dispensing patterns of drugs for secondary prevention of cardiovascular events and will also identify factors influencing these patterns. It will also assess the clinical and economic consequences of non-adherence and the cost-effectiveness of using these drugs.

Methods and analysis
This population-based cohort study will use longitudinal data on almost 40 000 people aged 65 years or older who were hospitalised in Western Australia between 2003 and 2008 for coronary heart disease, heart failure or atrial fibrillation. Linking of several State and Federal government administrative data sets will provide person-based information on drugs dispensed precardiac and postcardiac event, reasons for hospital admission, emergency department visits, mortality and medical visits. Dispensed drug trends will be described, drug adherence measured and their association with future all-cause/cardiovascular events will be estimated. The cost-effectiveness of these long-term therapies for cardiac disease and the impact of adherence will be evaluated.

Ethics and dissemination
Human Research Ethics Committee (HREC) approvals have been obtained from the Department of Health (Western Australian #2011/62 and Federal) and the University of Western Australia (RA/4/1/1130), in addition to HREC approvals from all participating hospitals. Findings will be published in peer-reviewed medical journals and presented at local, national and international conferences. Results will also be disseminated to consumer groups.

Original languageEnglish
Pages (from-to)e006258
JournalBMJ Open
Volume4
Issue number9
DOIs
Publication statusPublished - 18 Sep 2014

Fingerprint

Secondary Prevention
Cost-Benefit Analysis
Heart Diseases
Pharmaceutical Preparations
Western Australia
Research Ethics Committees
State Government
Federal Government
Medication Adherence
Mortality
Health Policy
Ethics
Atrial Fibrillation
Coronary Disease
Hospital Emergency Service
Cohort Studies
Heart Failure
Economics
Clinical Trials
Guidelines

Cite this

@article{406785d51f014f108d5ae9c5f9d55221,
title = "Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol",
abstract = "Introduction Secondary prevention drugs for cardiac disease have been demonstrated by clinical trials to be effective in reducing future cardiovascular and mortality events (WAMACH is the Western Australian Medication Adherence and Costs in Heart disease study). Hence, most countries have adopted health policies and guidelines for the use of these drugs, and included them in government subsidised drug lists to encourage their use. However, suboptimal prescribing and non-adherence to these drugs remains a universal problem. Our study will investigate trends in dispensing patterns of drugs for secondary prevention of cardiovascular events and will also identify factors influencing these patterns. It will also assess the clinical and economic consequences of non-adherence and the cost-effectiveness of using these drugs. Methods and analysis This population-based cohort study will use longitudinal data on almost 40 000 people aged 65 years or older who were hospitalised in Western Australia between 2003 and 2008 for coronary heart disease, heart failure or atrial fibrillation. Linking of several State and Federal government administrative data sets will provide person-based information on drugs dispensed precardiac and postcardiac event, reasons for hospital admission, emergency department visits, mortality and medical visits. Dispensed drug trends will be described, drug adherence measured and their association with future all-cause/cardiovascular events will be estimated. The cost-effectiveness of these long-term therapies for cardiac disease and the impact of adherence will be evaluated. Ethics and dissemination Human Research Ethics Committee (HREC) approvals have been obtained from the Department of Health (Western Australian #2011/62 and Federal) and the University of Western Australia (RA/4/1/1130), in addition to HREC approvals from all participating hospitals. Findings will be published in peer-reviewed medical journals and presented at local, national and international conferences. Results will also be disseminated to consumer groups.",
author = "Anthony Gunnell and Matthew Knuiman and Elizabeth Geelhoed and Michael Hobbs and Judith Katzenellenbogen and Joe Hung and J.M. Rankin and Lee Nedkoff and Tom Briffa and M. Ortiz and M. Gillies and A. Cordingley and M. Messer and Christian Gardner and Derrick Lopez and Emily Atkins and Qun Mai and Frank Sanfilippo",
year = "2014",
month = "9",
day = "18",
doi = "10.1136/bmjopen-2014-006258",
language = "English",
volume = "4",
pages = "e006258",
journal = "BMJ (Open)",
issn = "2044-6055",
publisher = "John Wiley & Sons",
number = "9",

}

Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol. / Gunnell, Anthony; Knuiman, Matthew; Geelhoed, Elizabeth; Hobbs, Michael; Katzenellenbogen, Judith; Hung, Joe; Rankin, J.M.; Nedkoff, Lee; Briffa, Tom; Ortiz, M.; Gillies, M.; Cordingley, A.; Messer, M.; Gardner, Christian; Lopez, Derrick; Atkins, Emily; Mai, Qun; Sanfilippo, Frank.

In: BMJ Open, Vol. 4, No. 9, 18.09.2014, p. e006258.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol

AU - Gunnell, Anthony

AU - Knuiman, Matthew

AU - Geelhoed, Elizabeth

AU - Hobbs, Michael

AU - Katzenellenbogen, Judith

AU - Hung, Joe

AU - Rankin, J.M.

AU - Nedkoff, Lee

AU - Briffa, Tom

AU - Ortiz, M.

AU - Gillies, M.

AU - Cordingley, A.

AU - Messer, M.

AU - Gardner, Christian

AU - Lopez, Derrick

AU - Atkins, Emily

AU - Mai, Qun

AU - Sanfilippo, Frank

PY - 2014/9/18

Y1 - 2014/9/18

N2 - Introduction Secondary prevention drugs for cardiac disease have been demonstrated by clinical trials to be effective in reducing future cardiovascular and mortality events (WAMACH is the Western Australian Medication Adherence and Costs in Heart disease study). Hence, most countries have adopted health policies and guidelines for the use of these drugs, and included them in government subsidised drug lists to encourage their use. However, suboptimal prescribing and non-adherence to these drugs remains a universal problem. Our study will investigate trends in dispensing patterns of drugs for secondary prevention of cardiovascular events and will also identify factors influencing these patterns. It will also assess the clinical and economic consequences of non-adherence and the cost-effectiveness of using these drugs. Methods and analysis This population-based cohort study will use longitudinal data on almost 40 000 people aged 65 years or older who were hospitalised in Western Australia between 2003 and 2008 for coronary heart disease, heart failure or atrial fibrillation. Linking of several State and Federal government administrative data sets will provide person-based information on drugs dispensed precardiac and postcardiac event, reasons for hospital admission, emergency department visits, mortality and medical visits. Dispensed drug trends will be described, drug adherence measured and their association with future all-cause/cardiovascular events will be estimated. The cost-effectiveness of these long-term therapies for cardiac disease and the impact of adherence will be evaluated. Ethics and dissemination Human Research Ethics Committee (HREC) approvals have been obtained from the Department of Health (Western Australian #2011/62 and Federal) and the University of Western Australia (RA/4/1/1130), in addition to HREC approvals from all participating hospitals. Findings will be published in peer-reviewed medical journals and presented at local, national and international conferences. Results will also be disseminated to consumer groups.

AB - Introduction Secondary prevention drugs for cardiac disease have been demonstrated by clinical trials to be effective in reducing future cardiovascular and mortality events (WAMACH is the Western Australian Medication Adherence and Costs in Heart disease study). Hence, most countries have adopted health policies and guidelines for the use of these drugs, and included them in government subsidised drug lists to encourage their use. However, suboptimal prescribing and non-adherence to these drugs remains a universal problem. Our study will investigate trends in dispensing patterns of drugs for secondary prevention of cardiovascular events and will also identify factors influencing these patterns. It will also assess the clinical and economic consequences of non-adherence and the cost-effectiveness of using these drugs. Methods and analysis This population-based cohort study will use longitudinal data on almost 40 000 people aged 65 years or older who were hospitalised in Western Australia between 2003 and 2008 for coronary heart disease, heart failure or atrial fibrillation. Linking of several State and Federal government administrative data sets will provide person-based information on drugs dispensed precardiac and postcardiac event, reasons for hospital admission, emergency department visits, mortality and medical visits. Dispensed drug trends will be described, drug adherence measured and their association with future all-cause/cardiovascular events will be estimated. The cost-effectiveness of these long-term therapies for cardiac disease and the impact of adherence will be evaluated. Ethics and dissemination Human Research Ethics Committee (HREC) approvals have been obtained from the Department of Health (Western Australian #2011/62 and Federal) and the University of Western Australia (RA/4/1/1130), in addition to HREC approvals from all participating hospitals. Findings will be published in peer-reviewed medical journals and presented at local, national and international conferences. Results will also be disseminated to consumer groups.

U2 - 10.1136/bmjopen-2014-006258

DO - 10.1136/bmjopen-2014-006258

M3 - Article

VL - 4

SP - e006258

JO - BMJ (Open)

JF - BMJ (Open)

SN - 2044-6055

IS - 9

ER -